CAPECITABINE, Fluorouracil 50 mg/ml Solution for Injection or Infusion, Oxaliplatin 5mg/ml concentrate for solution for infusion, CETUXIMAB, ENCORAFENIB, Calcium Folinate 10 mg/ml Injection, CAMPTO 20 mg/mL concentrate for solution for infusion, Irinotecan hydrochloride 20 mg/ml concentrate for solution for infusion, CAMPTO 20 mg/mL concentrate for solution for infusion, FLUOROURACIL, IRINOTECAN, Bevacizumab, CALCIUM FOLINATE, Capecitabine, Cetuximab, OXALIPLATIN, Oxaliplatin 5mg/ml concentrate for Solution

Quick answer

CAPECITABINE, Fluorouracil 50 mg/ml Solution for Injection or Infusion, Oxaliplatin 5mg/ml concentrate for solution for infusion, CETUXIMAB, ENCORAFENIB, Calcium Folinate 10 mg/ml Injection, CAMPTO 20 mg/mL concentrate for solution for infusion, Irinotecan hydrochloride 20 mg/ml concentrate for solution for infusion, CAMPTO 20 mg/mL concentrate for solution for infusion, FLUOROURACIL, IRINOTECAN, Bevacizumab, CALCIUM FOLINATE, Capecitabine, Cetuximab, OXALIPLATIN, Oxaliplatin 5mg/ml concentrate for Solution for Colorectal cancer (BRAF V600E-mutant mCRC) is a Phase 3 program (small_molecule) at Pfizer Ireland Pharmaceuticals Unlimited Company with 1 ClinicalTrials.gov record(s).